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Editorial
The challenge of diagnosing tuberculosis in children
O desafio de diagnosticar a infecção tuberculosa na criança
El desafío de diagnosticar la infección tuberculosa en el niño
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While we have made some progress towards the 
Millennium Development Goals(1), which were agreed in 
2010 by the World Health Organization – “to reduce by 
half the incidence and mortality of Tuberculosis by 2015, 
compared to values of 1990” –, Brazil still ranks 17th among 
countries with the highest TB burden in the world(2). The 
early and effective treatment of all cases of tuberculosis is 
the primary measure to save around 1.5 million lives each 
year(2). However, often, when diagnosis and treatment are 
being performed, many people (contacts) have already been 
infected, most of them children who, besides controlling less 
effectively the replication of the M. tuberculosis, progress more 
rapidly and frequently to pulmonary and extrapulmonary 
forms of the disease(3-5).
The identification and treatment of latent tuberculosis 
infection reduce the risk of progression to the active disease, 
particularly in high-risk groups, such as children under 5 
years old, infected with HIV and on immunosuppressive 
therapy(6,7). However, an early and accurate diagnosis of 
TB infection in children is still a great challenge. In addi-
tion to the tuberculin skin test - TST (used for over 100 
years), in the last decade researchers have developed tests 
using peripheral blood samples that measure the release 
of interferon-gamma (IFN-γ) from T host cells infected 
by M. tuberculosis(8). These tests, called Interferon-Gamma 
Release Assays (IGRAs), present advantages in relation to 
the tuberculin test: the results may be obtained in one or 
two days, do not require return visits for reading the skin 
reaction and, if repeated, do not present a booster effect. 
The three antigens used for the IGRA tests (ESAT-6, CFP-
10, and TB7.7) are not contained in BCG vaccine and in 
most other mycobacteria, while tuberculin (PPD) contains 
more than 200 antigens, which reduces its specificity. 
Two commercial kits are available: QuantiFERON-TB 
Gold in Tube, which assesses the levels of IFN-γ produced 
after antigen stimulation, and the T-Spot.TB test, which 
quantifies the mononuclear cells producing IFN-γ after in 
vitro stimulation. 
Over the past 3 years, three systematic reviews and meta-
analyzes have been published(9-11), concerning the IGRA tests 
in the pediatric population, revealing a very high specificity 
(95-100%) - exceeding that of the Tuberculin Test (TST) -, 
and  a lower sensitivity (80-90%), depending on the age of 
the subjects and their condition of imunocompetence (8-11). 
This suggests that the TST and the IGRAs have similar ac-
curacy in detecting infection or disease in children, but the 
interpretation of results is difficult due to the absence of a 
definitive marker of these conditions in children. 
The study by Vallada et al(12), published in this issue 
of the journal, assessed the accuracy of one Igra tests 
(QuantiFERON-TB Gold in Tube) in the diagnosis of 
tuberculosis in children and showed a positive predictive 
value of 81.8% (95%CI 46.3-97.4), sensitivity of 81.8% 
(95%CI 48.2-97.2), and specificity of 98.8% (95%CI 
96-99.8). However, the small sample of children assessed 
with tuberculosis (latent or active disease) diminishes the 
power of the study in its definitive findings. A strong point 
of the research, however, is the low age of participants 
(seven of the 11 children were younger than 5 years and 
five presented a positive test). Only two children defined 
by the study criteria as infected presented a negative 
QuantiFERON-TB Gold in Tube test, both with active 
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disease and under 3 years of age. Even considering that the 
11 children have received BCG at birth, the test presented 
a good relationship with the TST, which was ≥10mm in 
the nine children who performed it. 
Important implications of the study are: the good relation-
ship with the tuberculin skin test, even in young children, 
and the fact that, despite its high negative predictive value, 
a negative test cannot rule out the diagnosis of tuberculosis 
(infection or disease) in children. If we seek greater specificity 
in children who received the BCG vaccine, the IGRA tests 
are better than the TST, but if we want greater sensitiv-
ity, both tests can be performed. In immunocompromised 
children, including those affected with HIV, the combina-
tion of both tests should be preferred. 
The Interferon-Gamma Release Assays have not been 
validated as a routine diagnostic procedure for tuberculosis 
in Brazil. The possibility of excluding tuberculosis infec-
tion in children vaccinated with BCG, and the positive 
tuberculin reactions make the IGRAs important instru-
ments to diagnose tuberculosis infection in our country. 
However, although more specific than the TST, these tests 
are not capable to differentiate latent tuberculosis infection 
from tuberculosis disease, which still requires clinical and 
radiological criteria for its definition. 
References
1. Stop TB Partnership; World Health Organization. The Global Plan to Stop TB 
2011-2015: Transforming the fight towards elimination of tuberculosis. Geneva: 
WHO; 2011.
2. World Health Organization. Global tuberculosis report 2012. Geneva: WHO; 2012.
3. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ et al. 
The natural history of childhood intra-thoracic tuberculosis: a critical 
review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 
2004;8:392-402.
4. Dye C, Williams BG. The population dynamics and control of tuberculosis. 
Science 2010;328:856-61. 
5. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we 
and where do we need to go? PLoS Pathog 2012;8:e1002607.
6. Parekh M, Schluger N. Treatment of latent tuberculosis infection. Ther Adv 
Respir Dis 2013;7:351-6.
7. Sociedade Brasileira de Pneumologia e Tisiologia para o Manejo da Asma - 
2012.  III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia 
e Tisiologia. J Bras Pneumol 2009;35:1018-48. 
8. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M et al. Use in routine 
clinical practice of two commercial blood tests for diagnosis of infection with 
Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34. 
9. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-
gamma release assays and childhood tuberculosis: systematic review and 
meta-analysis. Int J Tuberc Lung Dis 2011;15:1018-32.
10. Sun L, Xiao J, Miao Q, Feng WX, Wu XR, Yin QQ et al. Interferon gamma 
release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS 
Immunol Med Microbiol 2011;63:165-73.
11. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, 
Hanekom W et al. The utility of an interferon gamma release assay for diagnosis 
of latent tuberculosis infection and disease in children: a systematic review 
and meta-analysis. Pediatr Infect Dis J 2011;30:694-700.
12. Vallada MG, Okay TS, Del Negro GM, Antonio CA, Yamamoto L, Ramos SR. 
Acurácia do QuantiFERON-TB  Gold in Tube no diagnóstico de tuberculose 
em uma população pediátrica jovem previamente vacinada com BCG. Rev 
Paul Pediatr 2014;32:4-10.
